PPCB - Latest News
Propanc Biopharma, Inc. (PPCB), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $3.1M. Beta to the broader market is 3.27.
The article list below shows the most recent PPCB headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent PPCB Headlines
Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results
benzinga.com - Aug 27, 2026
Propanc Biopharma Inc. (NASDAQ:PPCB) stock surged on Thursday after compelling preclinical and early translational data for its primary drug candidat
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
globenewswire.com - Aug 27, 2026
MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc.
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
globenewswire.com - Aug 18, 2026
MELBOURNE, Australia, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc.
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
globenewswire.com - Aug 12, 2026
Further improvements can be made with complementary treatment modalities such as PRP that target the way cancer cells become malignant, invasive and s
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
globenewswire.com - Aug 6, 2026
MELBOURNE, Australia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc.
How News Affects PPCB Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PPCB's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked PPCB news questions
- What is the latest PPCB news headline?
- The most recent PPCB headline (Aug 27, 2026) is "Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the PPCB news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What PPCB news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual PPCB options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.